R A N D O M I Z E. Observation (OBS) vs Rituximab Maintenance (MR). CVP x 6-8 → PR/CR (cyclophosphamide, vincristine, prednisone). Rituximab Maintenance: Stage III/IV Follicular Lymphoma (ECOG/CALGB E1496). Subset: 237 FL pts. P = .03 (one-sided).
Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.
Rituximab Maintenance (MR)
CVP x 6-8 → PR/CR
Subset: 237 FL pts
P = .03 (one-sided)
CVP x 4
CVP x 4
R-CVP x 4
Stage III/IV FL→
CVP = cyclophosphamide, vincristine, prednisone
CHOP vs R-CHOP → Observation vs Maintenance Rituximab
Benefit with maintenance rituximab even after R-CHOP
FCM vs R-FCM → Observation vs Maintenance Rituximab
( vs 17 months in the observation arm)
for MR not reached(vs 26 months in the observation arm)
Van Oers et al. ASH 2005. Abstract 353.
Hiddemann et al. ASH 2005. Abstract 920.
RICOVER-60:Interim analysis (n=828)
6 CYCLES vs 8 CYCLES
-No differences for entire population
-Small nonsignificant benefit for CHOP-14, 8 vs 6
-No benefit for R-CHOP-14, 8 vs 6
R-CHOP-14 vs CHOP-14
-CR, 81% vs 73% (P = .008)
-Time to treatment failure (at 26 months), 70% vs 57% (P = .000025)
HOVON/Nordic Lymphoma Group:Interim analysis (n=250)–DLBCL, FL, MCL
CHOP-14 x 8 v R-CHOP-14 x 8
-CR, No difference
Failure-free survival (at 18 months) favors R-CHOP-14: 51% vs 33%, P = .005
Dose-dense R-CHOP is feasible and produces results
superior to dose-dense CHOP. Results need to be confirmed.
*61-80 years of age
Phase 1/2 Initial Therapy With Fludarabine
and Thalidomide in Stage I-IV CLL
-10 CR (77%), 3 PR (23%)
-Overall response rate, intent-to-treat population 100%
(diarrhea, fatigue, pedal edema)
Phase 2 Study of Lenalidomide
in Relapsed/Refractory CLL
-2 CR (11.7%), 9 PR (52.9%), 5 SD (24.9%), 1 PD